| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 63 | 2024 | 802 | 9.440 |
Why?
|
| Melanoma | 22 | 2024 | 839 | 2.410 |
Why?
|
| Carcinoma, Basal Cell | 18 | 2024 | 69 | 2.250 |
Why?
|
| Dermatologic Surgical Procedures | 8 | 2021 | 45 | 2.250 |
Why?
|
| Mohs Surgery | 9 | 2024 | 39 | 1.780 |
Why?
|
| Aminoquinolines | 6 | 2010 | 35 | 1.400 |
Why?
|
| Skin Diseases | 9 | 2024 | 121 | 1.290 |
Why?
|
| Skin | 11 | 2024 | 503 | 1.150 |
Why?
|
| Suture Techniques | 6 | 2021 | 199 | 1.110 |
Why?
|
| Psoriasis | 3 | 2024 | 45 | 1.110 |
Why?
|
| Nose Neoplasms | 4 | 2022 | 31 | 1.090 |
Why?
|
| Head and Neck Neoplasms | 3 | 2020 | 469 | 1.060 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 12 | 0.950 |
Why?
|
| Hemochromatosis | 1 | 2024 | 33 | 0.900 |
Why?
|
| Scalp | 5 | 2020 | 56 | 0.870 |
Why?
|
| Hidrocystoma | 2 | 2020 | 4 | 0.840 |
Why?
|
| Surgical Flaps | 5 | 2022 | 204 | 0.830 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2020 | 15 | 0.820 |
Why?
|
| Adjuvants, Immunologic | 5 | 2007 | 359 | 0.800 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2024 | 648 | 0.790 |
Why?
|
| Apocrine Glands | 2 | 2020 | 4 | 0.770 |
Why?
|
| Biopsy | 13 | 2018 | 1244 | 0.760 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 331 | 0.760 |
Why?
|
| Humans | 114 | 2024 | 121933 | 0.740 |
Why?
|
| Patient Positioning | 1 | 2021 | 54 | 0.710 |
Why?
|
| Surgeons | 1 | 2024 | 243 | 0.680 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 815 | 0.670 |
Why?
|
| Skin Physiological Phenomena | 1 | 2018 | 19 | 0.640 |
Why?
|
| Leiomyosarcoma | 2 | 2010 | 30 | 0.640 |
Why?
|
| Nails | 3 | 2024 | 17 | 0.630 |
Why?
|
| Neck | 2 | 2014 | 133 | 0.620 |
Why?
|
| Tinea | 2 | 2018 | 6 | 0.620 |
Why?
|
| Diagnosis, Differential | 20 | 2021 | 1871 | 0.600 |
Why?
|
| Dermatology | 6 | 2008 | 34 | 0.570 |
Why?
|
| Carcinoid Tumor | 1 | 2017 | 21 | 0.570 |
Why?
|
| Immunologic Factors | 2 | 2010 | 176 | 0.560 |
Why?
|
| Ultraviolet Rays | 6 | 2024 | 203 | 0.560 |
Why?
|
| Space Flight | 1 | 2018 | 116 | 0.560 |
Why?
|
| Male | 50 | 2024 | 59266 | 0.530 |
Why?
|
| Hospitalization | 1 | 2024 | 1724 | 0.520 |
Why?
|
| Middle Aged | 35 | 2024 | 25447 | 0.520 |
Why?
|
| Fluorouracil | 3 | 2010 | 141 | 0.500 |
Why?
|
| Facial Neoplasms | 4 | 2017 | 19 | 0.480 |
Why?
|
| Rhinoplasty | 2 | 2021 | 44 | 0.470 |
Why?
|
| Cheek | 4 | 2017 | 23 | 0.450 |
Why?
|
| Needlestick Injuries | 2 | 2003 | 6 | 0.440 |
Why?
|
| Aged | 24 | 2024 | 18505 | 0.440 |
Why?
|
| Bandages | 2 | 2008 | 56 | 0.440 |
Why?
|
| Nose | 3 | 2022 | 93 | 0.430 |
Why?
|
| Female | 42 | 2024 | 64626 | 0.420 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 558 | 0.420 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 192 | 0.410 |
Why?
|
| Carcinoma | 1 | 2014 | 282 | 0.400 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 6103 | 0.400 |
Why?
|
| Adult | 25 | 2024 | 28681 | 0.400 |
Why?
|
| Melanoma, Amelanotic | 1 | 2011 | 2 | 0.390 |
Why?
|
| Penile Neoplasms | 2 | 2002 | 32 | 0.390 |
Why?
|
| Face | 3 | 2001 | 181 | 0.380 |
Why?
|
| Toes | 2 | 2008 | 25 | 0.380 |
Why?
|
| Porokeratosis | 1 | 2010 | 2 | 0.370 |
Why?
|
| Skin Diseases, Infectious | 2 | 2018 | 24 | 0.370 |
Why?
|
| Nevus | 2 | 2016 | 36 | 0.370 |
Why?
|
| Cicatrix | 2 | 2022 | 124 | 0.370 |
Why?
|
| Antimetabolites | 1 | 2010 | 32 | 0.370 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 999 | 0.360 |
Why?
|
| Surgical Instruments | 2 | 2008 | 57 | 0.350 |
Why?
|
| Lacerations | 1 | 2010 | 34 | 0.350 |
Why?
|
| Nail Diseases | 4 | 2003 | 14 | 0.350 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 1613 | 0.340 |
Why?
|
| Drug Eruptions | 2 | 2007 | 33 | 0.340 |
Why?
|
| Skin Transplantation | 2 | 2001 | 60 | 0.330 |
Why?
|
| Dermatitis, Irritant | 1 | 2009 | 4 | 0.330 |
Why?
|
| Pruritus | 2 | 2024 | 41 | 0.330 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2009 | 3 | 0.330 |
Why?
|
| Plants | 1 | 2009 | 46 | 0.320 |
Why?
|
| Ear Neoplasms | 2 | 2008 | 12 | 0.320 |
Why?
|
| Case-Control Studies | 4 | 2024 | 3226 | 0.310 |
Why?
|
| Ear Auricle | 1 | 2008 | 4 | 0.310 |
Why?
|
| Hair Diseases | 1 | 2008 | 14 | 0.300 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2008 | 12 | 0.300 |
Why?
|
| Foreign-Body Reaction | 1 | 2008 | 14 | 0.300 |
Why?
|
| Epidermal Cyst | 1 | 2008 | 19 | 0.300 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2017 | 21 | 0.300 |
Why?
|
| Fingers | 1 | 2008 | 64 | 0.290 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 287 | 0.290 |
Why?
|
| Xylans | 1 | 2006 | 3 | 0.260 |
Why?
|
| Hemangiopericytoma | 1 | 2006 | 10 | 0.260 |
Why?
|
| Organ Transplantation | 3 | 2004 | 163 | 0.250 |
Why?
|
| Carcinoma in Situ | 2 | 2002 | 69 | 0.250 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 10 | 0.240 |
Why?
|
| Complementary Therapies | 1 | 2024 | 42 | 0.230 |
Why?
|
| California | 1 | 2024 | 122 | 0.230 |
Why?
|
| Gloves, Surgical | 1 | 2003 | 4 | 0.230 |
Why?
|
| Needles | 1 | 2003 | 52 | 0.220 |
Why?
|
| Light | 1 | 2024 | 175 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2024 | 199 | 0.210 |
Why?
|
| Interferon Inducers | 1 | 2002 | 6 | 0.210 |
Why?
|
| Competitive Behavior | 1 | 2002 | 10 | 0.210 |
Why?
|
| Risk Factors | 5 | 2024 | 9686 | 0.210 |
Why?
|
| Lentigo | 2 | 2000 | 2 | 0.210 |
Why?
|
| Paget Disease, Extramammary | 1 | 2002 | 4 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 64 | 0.200 |
Why?
|
| Nose Deformities, Acquired | 1 | 2021 | 12 | 0.200 |
Why?
|
| Lip Neoplasms | 1 | 2021 | 4 | 0.200 |
Why?
|
| Anesthesia, Local | 1 | 2002 | 47 | 0.190 |
Why?
|
| Lipodystrophy | 1 | 2001 | 34 | 0.190 |
Why?
|
| Shock, Septic | 1 | 2003 | 148 | 0.190 |
Why?
|
| Fish Oils | 3 | 1992 | 82 | 0.190 |
Why?
|
| Lipoma | 1 | 2021 | 23 | 0.190 |
Why?
|
| Muscle Neoplasms | 1 | 2021 | 21 | 0.190 |
Why?
|
| Anesthetics, Local | 1 | 2002 | 79 | 0.190 |
Why?
|
| Consensus | 1 | 2024 | 605 | 0.190 |
Why?
|
| United States | 6 | 2024 | 10434 | 0.190 |
Why?
|
| Curettage | 1 | 2000 | 6 | 0.180 |
Why?
|
| Smoking | 2 | 2024 | 1027 | 0.180 |
Why?
|
| Medicare | 1 | 2024 | 417 | 0.180 |
Why?
|
| Prevalence | 3 | 2024 | 2371 | 0.180 |
Why?
|
| Administration, Topical | 4 | 2007 | 143 | 0.180 |
Why?
|
| Pigmentation | 1 | 2020 | 36 | 0.180 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 257 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 650 | 0.180 |
Why?
|
| Inpatients | 1 | 2024 | 487 | 0.180 |
Why?
|
| Antifungal Agents | 3 | 1999 | 293 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2002 | 258 | 0.180 |
Why?
|
| Masks | 1 | 2020 | 36 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 131 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2002 | 268 | 0.170 |
Why?
|
| Hospital Mortality | 1 | 2024 | 977 | 0.160 |
Why?
|
| Hidradenitis Suppurativa | 1 | 1998 | 4 | 0.160 |
Why?
|
| Dermatitis, Contact | 1 | 2018 | 7 | 0.160 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 81 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 2 | 1999 | 278 | 0.160 |
Why?
|
| Dermis | 1 | 2018 | 24 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 67 | 0.160 |
Why?
|
| Urticaria | 1 | 2018 | 20 | 0.160 |
Why?
|
| Epidermis | 1 | 2018 | 61 | 0.160 |
Why?
|
| Eczema | 1 | 2018 | 28 | 0.160 |
Why?
|
| Aerospace Medicine | 1 | 2018 | 37 | 0.160 |
Why?
|
| Pigmentation Disorders | 1 | 1998 | 23 | 0.160 |
Why?
|
| Erythema | 4 | 1999 | 24 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 70 | 0.150 |
Why?
|
| Dermatitis, Atopic | 1 | 2018 | 40 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.150 |
Why?
|
| CREST Syndrome | 1 | 2017 | 5 | 0.150 |
Why?
|
| Multiple Sclerosis | 1 | 2001 | 333 | 0.150 |
Why?
|
| Peptides | 1 | 2001 | 799 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 252 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3289 | 0.150 |
Why?
|
| Collagen | 1 | 2018 | 312 | 0.140 |
Why?
|
| Bowen's Disease | 3 | 2009 | 4 | 0.140 |
Why?
|
| Prognosis | 6 | 2017 | 4485 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 184 | 0.140 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 46 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 354 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1116 | 0.130 |
Why?
|
| Keratin-7 | 1 | 2014 | 7 | 0.120 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2014 | 14 | 0.120 |
Why?
|
| Shoulder | 2 | 2006 | 28 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 27 | 0.120 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 231 | 0.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 61 | 0.120 |
Why?
|
| Thyroidectomy | 1 | 2014 | 101 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 76 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 1680 | 0.110 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1711 | 0.110 |
Why?
|
| Hyperpigmentation | 2 | 2005 | 13 | 0.110 |
Why?
|
| Microbiota | 1 | 2018 | 392 | 0.110 |
Why?
|
| Sutures | 2 | 2008 | 67 | 0.110 |
Why?
|
| Skin Pigmentation | 4 | 2001 | 27 | 0.110 |
Why?
|
| Margins of Excision | 3 | 2017 | 51 | 0.110 |
Why?
|
| Stents | 1 | 1998 | 685 | 0.110 |
Why?
|
| Keratosis | 4 | 2007 | 16 | 0.110 |
Why?
|
| Telemedicine | 1 | 2018 | 422 | 0.100 |
Why?
|
| Barbering | 1 | 2011 | 1 | 0.100 |
Why?
|
| Administration, Cutaneous | 2 | 2010 | 60 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2024 | 11702 | 0.100 |
Why?
|
| Time Factors | 2 | 2014 | 5997 | 0.100 |
Why?
|
| Desmin | 1 | 2010 | 21 | 0.090 |
Why?
|
| Surface Properties | 1 | 2010 | 76 | 0.090 |
Why?
|
| Pressure | 1 | 2010 | 128 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2010 | 77 | 0.090 |
Why?
|
| Remission Induction | 1 | 2010 | 301 | 0.090 |
Why?
|
| Nicotinic Acids | 1 | 2009 | 6 | 0.090 |
Why?
|
| Leg | 1 | 2010 | 152 | 0.090 |
Why?
|
| Dermatitis, Occupational | 1 | 2009 | 2 | 0.080 |
Why?
|
| Patch Tests | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 7 | 0.080 |
Why?
|
| Ectoparasitic Infestations | 1 | 2008 | 3 | 0.080 |
Why?
|
| Siphonaptera | 1 | 2008 | 6 | 0.080 |
Why?
|
| Nevus, Pigmented | 2 | 2005 | 33 | 0.080 |
Why?
|
| Naphthalenes | 2 | 1999 | 37 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3072 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1283 | 0.080 |
Why?
|
| Actins | 1 | 2010 | 341 | 0.080 |
Why?
|
| Adolescent | 3 | 2024 | 18941 | 0.080 |
Why?
|
| Melanocytes | 2 | 2006 | 47 | 0.070 |
Why?
|
| Travel | 1 | 2008 | 117 | 0.070 |
Why?
|
| Incidence | 4 | 2011 | 2997 | 0.070 |
Why?
|
| Cheilitis | 1 | 2007 | 1 | 0.070 |
Why?
|
| Immunization | 1 | 2009 | 303 | 0.070 |
Why?
|
| Ointments | 1 | 2007 | 14 | 0.070 |
Why?
|
| Mice, Hairless | 2 | 2002 | 30 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 4990 | 0.070 |
Why?
|
| Ankle | 1 | 2007 | 27 | 0.070 |
Why?
|
| Dietary Fats | 1 | 1989 | 288 | 0.070 |
Why?
|
| Recurrence | 2 | 2001 | 1396 | 0.070 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2005 | 1 | 0.070 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2005 | 4 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2008 | 170 | 0.070 |
Why?
|
| Idarubicin | 1 | 2005 | 7 | 0.060 |
Why?
|
| Histiocytosis, Sinus | 1 | 2006 | 30 | 0.060 |
Why?
|
| Warts | 2 | 2003 | 11 | 0.060 |
Why?
|
| Allylamine | 2 | 1997 | 8 | 0.060 |
Why?
|
| Surgical Equipment | 1 | 2004 | 4 | 0.060 |
Why?
|
| Capsaicin | 1 | 2024 | 17 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1987 | 118 | 0.060 |
Why?
|
| Mercaptopurine | 1 | 2005 | 71 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 89 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 129 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2014 | 2586 | 0.060 |
Why?
|
| Dermatologic Agents | 2 | 2009 | 30 | 0.060 |
Why?
|
| Phototherapy | 1 | 2024 | 35 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 178 | 0.060 |
Why?
|
| Child | 1 | 2024 | 24081 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2004 | 70 | 0.060 |
Why?
|
| Patient Care Management | 1 | 2004 | 65 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2003 | 122 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2003 | 9 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1681 | 0.050 |
Why?
|
| Mycobacterium | 1 | 2003 | 29 | 0.050 |
Why?
|
| Glomus Tumor | 1 | 2003 | 9 | 0.050 |
Why?
|
| Aspergillus | 1 | 2003 | 31 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2003 | 26 | 0.050 |
Why?
|
| Enterobacteriaceae | 1 | 2003 | 34 | 0.050 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2003 | 25 | 0.050 |
Why?
|
| Internet | 1 | 2006 | 373 | 0.050 |
Why?
|
| Leishmania | 1 | 2003 | 27 | 0.050 |
Why?
|
| Syringes | 1 | 2002 | 24 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 427 | 0.050 |
Why?
|
| Candida | 1 | 2003 | 75 | 0.050 |
Why?
|
| Celecoxib | 1 | 2002 | 31 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2002 | 69 | 0.050 |
Why?
|
| Microsurgery | 1 | 2002 | 69 | 0.050 |
Why?
|
| Glatiramer Acetate | 1 | 2001 | 11 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2002 | 76 | 0.050 |
Why?
|
| Arm | 1 | 2002 | 73 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2005 | 281 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2009 | 3223 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2002 | 47 | 0.050 |
Why?
|
| Scapula | 1 | 2021 | 12 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 319 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 126 | 0.050 |
Why?
|
| Animals | 7 | 2008 | 33736 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 416 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 418 | 0.050 |
Why?
|
| Calibration | 1 | 2001 | 82 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2001 | 38 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 646 | 0.050 |
Why?
|
| Dermatomycoses | 2 | 1991 | 15 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2002 | 182 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 2799 | 0.050 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 58 | 0.050 |
Why?
|
| Documentation | 1 | 2001 | 115 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1032 | 0.040 |
Why?
|
| Photography | 1 | 2001 | 91 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 1999 | 22 | 0.040 |
Why?
|
| Cyclin E | 1 | 1999 | 30 | 0.040 |
Why?
|
| Sex Factors | 2 | 2006 | 1231 | 0.040 |
Why?
|
| Physical Examination | 1 | 2001 | 162 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1082 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 699 | 0.040 |
Why?
|
| Benzylamines | 1 | 1999 | 17 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2002 | 299 | 0.040 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1999 | 4 | 0.040 |
Why?
|
| Keratolytic Agents | 1 | 1998 | 3 | 0.040 |
Why?
|
| Furunculosis | 1 | 1998 | 4 | 0.040 |
Why?
|
| Isotretinoin | 1 | 1998 | 25 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 413 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 128 | 0.040 |
Why?
|
| Clindamycin | 1 | 1998 | 40 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1999 | 76 | 0.040 |
Why?
|
| Hair Follicle | 1 | 1998 | 33 | 0.040 |
Why?
|
| Neoplasms | 2 | 1995 | 2753 | 0.040 |
Why?
|
| Mastic Resin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 426 | 0.040 |
Why?
|
| Resins, Plant | 1 | 1998 | 3 | 0.040 |
Why?
|
| Equipment Design | 1 | 2000 | 586 | 0.040 |
Why?
|
| Absorption | 1 | 1998 | 53 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 609 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 1998 | 8 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 244 | 0.040 |
Why?
|
| Econazole | 1 | 1997 | 3 | 0.040 |
Why?
|
| Ketoconazole | 1 | 1997 | 11 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 542 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 439 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2016 | 15630 | 0.040 |
Why?
|
| Epithelium | 1 | 1998 | 372 | 0.040 |
Why?
|
| Surgical Mesh | 1 | 1998 | 61 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2008 | 0.040 |
Why?
|
| Chemoprevention | 1 | 1997 | 60 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 622 | 0.040 |
Why?
|
| Tattooing | 1 | 1996 | 6 | 0.040 |
Why?
|
| Plant Extracts | 1 | 1998 | 117 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1997 | 215 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1999 | 466 | 0.030 |
Why?
|
| Pyridones | 1 | 1997 | 111 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 1999 | 415 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 599 | 0.030 |
Why?
|
| Imidazoles | 1 | 1997 | 200 | 0.030 |
Why?
|
| Immunocompromised Host | 2 | 1995 | 300 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 122 | 0.030 |
Why?
|
| Bites, Human | 1 | 1995 | 1 | 0.030 |
Why?
|
| Bites and Stings | 1 | 1995 | 30 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2002 | 856 | 0.030 |
Why?
|
| Cats | 1 | 1995 | 116 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 1999 | 660 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 303 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1900 | 0.030 |
Why?
|
| Herpesviridae | 1 | 1995 | 31 | 0.030 |
Why?
|
| Disposable Equipment | 1 | 1994 | 15 | 0.030 |
Why?
|
| Pedigree | 1 | 1998 | 1576 | 0.030 |
Why?
|
| Sunlight | 1 | 1994 | 22 | 0.030 |
Why?
|
| Young Adult | 3 | 2016 | 8750 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 1994 | 36 | 0.030 |
Why?
|
| Dogs | 1 | 1995 | 775 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 1242 | 0.030 |
Why?
|
| Laser Therapy | 1 | 1996 | 244 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1994 | 70 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2002 | 1032 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 1993 | 7 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1514 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1995 | 493 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1997 | 1568 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 2 | 1995 | 120 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 1679 | 0.030 |
Why?
|
| Cysts | 1 | 1992 | 99 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 4284 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 1992 | 69 | 0.020 |
Why?
|
| Mice | 3 | 2002 | 17547 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 2482 | 0.020 |
Why?
|
| Base Sequence | 1 | 1995 | 3115 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 235 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 863 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3437 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1994 | 713 | 0.020 |
Why?
|
| Cryptococcosis | 1 | 1990 | 42 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2009 | 30 | 0.020 |
Why?
|
| Peace Corps | 1 | 2008 | 1 | 0.020 |
Why?
|
| Tanzania | 1 | 2008 | 66 | 0.020 |
Why?
|
| Hand | 1 | 2009 | 101 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 235 | 0.020 |
Why?
|
| Melanosis | 1 | 1987 | 10 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1984 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1243 | 0.020 |
Why?
|
| Mitoguazone | 1 | 1987 | 3 | 0.020 |
Why?
|
| Eflornithine | 1 | 1987 | 15 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2381 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2006 | 60 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2006 | 68 | 0.020 |
Why?
|
| Nucleoside Deaminases | 1 | 1985 | 27 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1146 | 0.020 |
Why?
|
| Parotid Neoplasms | 1 | 2005 | 15 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 1985 | 74 | 0.020 |
Why?
|
| Cytarabine | 1 | 2005 | 99 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 2005 | 85 | 0.020 |
Why?
|
| Leukemia | 1 | 1987 | 378 | 0.010 |
Why?
|
| Patient Care | 1 | 2004 | 99 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 267 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 3526 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 517 | 0.010 |
Why?
|
| DNA Repair | 1 | 2006 | 584 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 332 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 3623 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 354 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 539 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1999 | 59 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 1999 | 51 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1999 | 116 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 2771 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 90 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1999 | 233 | 0.010 |
Why?
|
| Frozen Sections | 1 | 1998 | 24 | 0.010 |
Why?
|
| Ear, External | 1 | 1998 | 22 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 1998 | 83 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 1999 | 278 | 0.010 |
Why?
|
| Rabies | 1 | 1995 | 11 | 0.010 |
Why?
|
| Habits | 1 | 1995 | 26 | 0.010 |
Why?
|
| Dermatitis, Seborrheic | 1 | 1995 | 3 | 0.010 |
Why?
|
| Globins | 1 | 1995 | 35 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1995 | 33 | 0.010 |
Why?
|
| Connective Tissue Diseases | 1 | 1995 | 28 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1995 | 135 | 0.010 |
Why?
|
| India | 1 | 1995 | 218 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1995 | 115 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 223 | 0.010 |
Why?
|
| Alcoholism | 1 | 1995 | 229 | 0.010 |
Why?
|
| Trichophyton | 1 | 1991 | 1 | 0.010 |
Why?
|
| Foot Dermatoses | 1 | 1991 | 7 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 1591 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1991 | 193 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1990 | 148 | 0.010 |
Why?
|
| Leukotriene B4 | 1 | 1988 | 7 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1995 | 857 | 0.000 |
Why?
|
| Ornithine Decarboxylase | 1 | 1987 | 18 | 0.000 |
Why?
|
| Putrescine | 1 | 1987 | 11 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1995 | 843 | 0.000 |
Why?
|
| Polyamines | 1 | 1987 | 28 | 0.000 |
Why?
|
| Coformycin | 1 | 1985 | 7 | 0.000 |
Why?
|
| Pentostatin | 1 | 1985 | 11 | 0.000 |
Why?
|
| Adenosine Deaminase Inhibitors | 1 | 1985 | 6 | 0.000 |
Why?
|
| Immunosorbent Techniques | 1 | 1985 | 26 | 0.000 |
Why?
|
| Isoelectric Focusing | 1 | 1985 | 23 | 0.000 |
Why?
|
| Half-Life | 1 | 1985 | 159 | 0.000 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1985 | 313 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1985 | 393 | 0.000 |
Why?
|
| Cell Division | 1 | 1987 | 796 | 0.000 |
Why?
|
| Gene Amplification | 1 | 1985 | 228 | 0.000 |
Why?
|
| Adenosine | 1 | 1985 | 126 | 0.000 |
Why?
|
| Kinetics | 1 | 1985 | 1317 | 0.000 |
Why?
|
| Diet | 1 | 1988 | 1105 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1987 | 3074 | 0.000 |
Why?
|
| Cell Line | 1 | 1985 | 2788 | 0.000 |
Why?
|
| Mutation | 1 | 1985 | 5766 | 0.000 |
Why?
|